Koyfin Home > Directory > Health Care > Adma Biologics > Long-Term Debt / Capital

Adma Biologics Long-Term Debt / Capital Chart (ADMA)

Adma Biologics annual/quarterly Long-Term Debt / Capital from 2010 to 2020.
  • Adma Biologics Long-Term Debt / Capital for the quarter ending June 06, 2020 was $56m a -23.91% decrease of -13m year over year
  • Adma Biologics Long-Term Debt / Capital for the last 12 months ending June 06, 2020 was $56m a -23.91% decrease of -13m year over year
  • Adma Biologics Annual Long-Term Debt / Capital for 2019 was $76m a 11.18% increase of 9m from 2018
  • Adma Biologics Annual Long-Term Debt / Capital for 2018 was $68m a 26.22% increase of 18m from 2017
  • Adma Biologics Annual Long-Term Debt / Capital for 2017 was $50m a -76.60% decrease of -38m from 2016
Other Ratios Metrics:
  • Adma Biologics Total Debt / Capital for the quarter ending September 09, 2018 was $53m a 4.96% increase of 3m year over year
  • Adma Biologics Other Liabilities for the quarter ending December 12, 2018 was $18m a -0.86% decrease of 0m year over year
  • Adma Biologics Total Debt / Equity for the quarter ending September 09, 2018 was $111m a 9.91% increase of 11m year over year
View Chart On Koyfin

Quarterly ADMA Long-Term Debt / Capital Data

06/2020$56m
03/2020$50m
12/2019$76m
09/2019$70m
06/2019$64m
03/2019$85m
12/2018$68m
09/2018$52m
06/2018$44m
03/2018$64m

Annual ADMA Long-Term Debt / Capital Data

2019$76m
2018$68m
2017$50m
2016$88m
2015$94m
2014$71m
2013$19m
2012$29m
2011$9m
2010$3m